Inaktiver Wert

Andere Sprachen RedHill Biopharma Ltd. OTC Markets

Aktien

A1JJWN

IL0011223810

REDIF

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

RedHill Biopharma Terminates License Agreement for Aemcolo	10.07.
Redhill Biopharma Ltd. Terminates License Agreement for Aemcolo	09.07.
RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board	06.06.
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K	03.06.
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	06.05.
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K	06.05.
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035	06.05.
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	06.05.
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K	24.04.
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	24.04.
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights	09.04.
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08.04.
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price	03.04.
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023	28.03.
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	11.03.
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K	05.03.
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs	05.03.
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	05.03.
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication	21.02.
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen RedHill Biopharma Ltd. OTC Markets

Aktien

A1JJWN

IL0011223810

REDIF

Andere Sprachen

Filter